Avalo Therapeutics, Inc. (AVTX) has a negative trailing P/E of -2.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -40.74%.
Criteria proven by this page:
Overall SharesGrow Score: 43/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.5 | -0.01 | 37.54 | 6.74 | - |
| 2017 | 5.0 | 0.00 | 2.11 | 2.12 | - |
| 2018 | -2.8 | 0.01 | 5.37 | 6.13 | - |
| 2019 | -19.2 | 0.25 | 14.68 | 45.65 | - |
| 2020 | -3.1 | -0.01 | 7.90 | 28.95 | - |
| 2021 | -2.1 | 0.27 | 7.68 | 32.83 | - |
| 2022 | -1.1 | 0.02 | -4.34 | 2.63 | - |
| 2023 | -0.1 | 0.00 | 0.35 | 1.31 | - |
| 2024 | -1.7 | 0.02 | 0.45 | 136.95 | - |
| 2025 | -3.1 | -0.09 | 2.93 | 4,125.96 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-21.93 | $1.15M | $-16.47M | -1428.5% |
| 2017 | $1,822.74 | $27.81M | $11.87M | 42.7% |
| 2018 | $-3,317.28 | $18.33M | $-40.05M | -218.5% |
| 2019 | $-819.74 | $6.75M | $-16.27M | -241.1% |
| 2020 | $-2,523.77 | $6.7M | $-64.38M | -961.1% |
| 2021 | $-2,330.66 | $5.4M | $-84.35M | -1562.6% |
| 2022 | $-1,062.65 | $18.05M | $-41.66M | -230.8% |
| 2023 | $-113.58 | $1.92M | $-31.54M | -1639.5% |
| 2024 | $-3.26 | $441K | $-35.13M | -7965.8% |
| 2025 | $-5.84 | $59K | $-78.26M | -132642.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.56 | $-8.54 – $-2.91 | $1M | $1M – $1M | 6 |
| 2027 | $-3.99 | $-6.67 – $-1.74 | $1M | $1M – $1M | 6 |
| 2028 | $-3.95 | $-6.66 – $-2.20 | $13.88K | $13.88K – $13.88K | 6 |
| 2029 | $-3.91 | $-3.91 – $-3.91 | $11.05M | $11.05M – $11.05M | 4 |
| 2030 | $-2.18 | $-2.18 – $-2.18 | $119.9M | $119.9M – $119.9M | 2 |
